Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 24: Timing of Cardio-Kidney Protection with SGLT2i
Author(s): Muthiah Vaduganathan Added: 1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors.4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER. Across each… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Owais Dar , Espeed Khoshbin Added: 1 year ago
Heart transplantation and left ventricular assist devices (LVADs) are crucial options for patients with advanced heart failure, but determining the right timing for intervention is key to optimizing outcomes. This webinar, moderated by Dr Owais Dar from the Royal Brompton and Harefield Hospitals, will explore the decision-making process behind patient referrals, weighing the benefits and risks of… View more

Heart Failure
Timing of Heart Transplantation & LVADs
Author(s): Espeed Khoshbin , Owais Dar Start date: Nov 05, 2024
Heart transplantation and left ventricular assist devices (LVADs) are crucial options for patients with advanced heart failure, but determining the right timing for intervention is key to optimizing outcomes. This webinar, moderated by Dr Owais Dar from the Royal Brompton and Harefield Hospitals, will explore the decision-making process behind patient referrals, weighing the benefits and risks of… View more

Heart Failure
Research Area(s) / Expertise:
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC is the President-Elect of the American Society for Preventive Cardiology. She was a Professor of Medicine and the inaugural Chief of Cardiology at the University of Arizona. Previously, she held the Sarah Ross Soter Chair in Women’s Cardiovascular Health and was the Section Director for Women’s Cardiovascular Health and Preventive Cardiology at The… View more
Lorenzo Azzalini headshot
Job title: Director of Interventional Cardiology Research and Associate Professor of Medicine
Dr. Azzalini is the Director of Interventional Cardiology Research and Associate Professor of Medicine at University of Washington, in Seattle, WA.He graduated magna cum laude from University of Padua in Italy in 2006. He subsequently completed cardiology training, a master’s degree in research methodology and a PhD in medicine at the Autonomous University of Barcelona in Spain. He completed two… View more
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 2 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 1 month ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Clinical Clues in Cardiovascular Disease
Author(s): Yassir Javaid , Faizel Osman , Renate B Schnabel , et al Added: 3 months ago
This six-part interview series, recorded around ESC 2025, brings together leading experts to share strategies for earlier and more accurate detection of cardiovascular disease. The discussions highlight how atypical or subtle symptoms of stroke and heart failure can delay diagnosis, and why vigilance in routine practice is critical.The series also examines sex-specific differences in cardiac… View more

CV Disease in Special Populations

Electrophysiology & Arrhythmia
EHRA 24: The QDOT-by-LAWT Trial
Author(s): Giulio Falasconi Added: 1 year ago
EHRA 24 - In this video, investigator, Dr Giulio Falasconi (Humanitas Research Hospital, IT) joins us to discuss the findings from the QDOT-by-LAWT trial. This study included 162 patients with paroxysmal atrial fibrillation not responding to antiarrhythmic drugs. They were retrospectively enrolled and randomized on a 1:1 basis to the QDOT-by-LAWT study group, and the control group.Findings showed… View more

Electrophysiology & Arrhythmia
Author(s): Ubonwan Sapoo , Nuengruthai Phunpha , Patipan Pusopa , et al Added: 1 year ago

Anticoagulation